Ted Smolenski joined Slayback in June 2019, bringing approximately 20 years of pharmaceutical experience to the company. He leads
Slayback’s business development efforts by identifying partnership opportunities and driving business deals to successful close.
Most recently, Mr. Smolenski was Head of Business Development at Rhodes Pharmaceuticals, where he played a lead role in business
development and alliance management. Prior to Rhodes, Mr. Smolenski was Putney’s Vice President of Business Development and Portfolio
where he led Putney’s portfolio process and closed business deals to drive Putney’s growth. Earlier in his career, Mr. Smolenski was
Senior Director of Portfolio Management and Strategy at Impax Laboratories where his team had responsibility for portfolio strategy,
alliance management, API sourcing, and PIV settlement negotiation.
Mr. Smolenski holds a Bachelor’s Degree in Civil Engineering and a Master’s of Business Administration from the University of Delaware.